Bio Stocks™
@BioStocks
Followers
70K
Following
545
Media
1K
Statuses
59K
Investor/trader focused primarily in the biopharma sector. Tweets are not investment advice and are not recommendations of any kind.
Toronto
Joined February 2010
Just realized, I celebrate my 15th Twitterversary this month. Back then, I never imagined this app would become a second home. What started as a place to share ideas has grown into so much more. This platform has allowed me to share biotech insights, bounce ideas, and learn
10
1
129
$RCUS Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study. $GILD https://t.co/oeXHKVr6Kj
businesswire.com
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination thera...
4
1
10
But, why did this happen? To better understand, take a look at the timeline below: At 9:50 AM ET, crypto began selling off before the 10:57 AM ET Trump tariff post. At 4:30 PM ET, a large "whale" took shorts in crypto. At 4:50 PM ET, Trump announced a 100% tariff on China.
16
104
810
Crypto’s record selloff - more than 1.6 million traders liquidated. #CryptoCrash $BTC $ETH https://t.co/uaoMkD06Lv
finance.yahoo.com
Cryptocurrency prices tumbled on Friday after Trump said he would impose an additional 100% tariff on China and export controls on software. The declines precipitated, and then were made worse by...
0
3
10
$NVO Halts Cell Therapy Work on Diabetes to Cut Costs Almost all of the division's about 250 employees are expected to be laid off. https://t.co/0ZXbdMLgzu
bloomberg.com
Novo Nordisk A/S cut its cell therapy division, which has been trying to find a cure for type 1 diabetes, as the Ozempic maker continues to slash headcount to focus on lucrative areas of obesity and...
1
9
22
$OSTX Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma https://t.co/4d5a5hDpy4
newsfilecorp.com
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001)100%...
0
0
8
$TSHA Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at #CNS25
https://t.co/ha1k98X0o2
ir.tayshagtx.com
Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via...
0
1
7
$CDTX Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention
0
3
16
$AKRO $6 CVR payable upon full U.S. regulatory approval of Efruxifermin in MASH by June 30, 2031. $NVO
1
0
3
$NVO is acquiring $AKRO $54 per share plus a $6 VCR
16
9
72
Nasdaq Has Become the Market of Choice for Dubious Penny-Stock IPOs https://t.co/535CjiZ7x0
finance.yahoo.com
Such listings surged starting last year. Now Nasdaq says it wants to tighten its standards.
0
0
5